224 related articles for article (PubMed ID: 24389084)
1. Genome- and proteome-wide screening strategies for antigen discovery and immunogen design.
Schussek S; Trieu A; Doolan DL
Biotechnol Adv; 2014; 32(2):403-14. PubMed ID: 24389084
[TBL] [Abstract][Full Text] [Related]
2. Proteomics approaches towards antigen discovery and vaccine development.
Klade CS
Curr Opin Mol Ther; 2002 Jun; 4(3):216-23. PubMed ID: 12139306
[TBL] [Abstract][Full Text] [Related]
3. Designing the next generation of vaccines for global public health.
Bagnoli F; Baudner B; Mishra RP; Bartolini E; Fiaschi L; Mariotti P; Nardi-Dei V; Boucher P; Rappuoli R
OMICS; 2011 Sep; 15(9):545-66. PubMed ID: 21682594
[TBL] [Abstract][Full Text] [Related]
4. Developing vaccines in the era of genomics: a decade of reverse vaccinology.
Seib KL; Zhao X; Rappuoli R
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():109-16. PubMed ID: 22882709
[TBL] [Abstract][Full Text] [Related]
5. Developing antibacterial vaccines in genomics and proteomics era.
Kaushik DK; Sehgal D
Scand J Immunol; 2008 Jun; 67(6):544-52. PubMed ID: 18397199
[TBL] [Abstract][Full Text] [Related]
6. Integration of Novel Materials and Advanced Genomic Technologies into New Vaccine Design.
Liao W; Zhang TT; Gao L; Lee SS; Xu J; Zhang H; Yang Z; Liu Z; Li W
Curr Top Med Chem; 2017; 17(20):2286-2301. PubMed ID: 28240182
[TBL] [Abstract][Full Text] [Related]
7. Immunomics: a 21st century approach to vaccine development for complex pathogens.
De Sousa KP; Doolan DL
Parasitology; 2016 Feb; 143(2):236-44. PubMed ID: 26864136
[TBL] [Abstract][Full Text] [Related]
8. Characterizing vaccine responses using host genomic and transcriptomic analysis.
O'Connor D; Pollard AJ
Clin Infect Dis; 2013 Sep; 57(6):860-9. PubMed ID: 23728145
[TBL] [Abstract][Full Text] [Related]
9. Novel vaccine design based on genomics data analysis: A review.
Lu G; Shan S; Zainab B; Ayaz Z; He J; Xie Z; Rashid U; Zhang D; Mehmood Abbasi A
Scand J Immunol; 2021 Mar; 93(3):e12986. PubMed ID: 33043473
[TBL] [Abstract][Full Text] [Related]
10. Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens.
Serruto D; Adu-Bobie J; Capecchi B; Rappuoli R; Pizza M; Masignani V
J Biotechnol; 2004 Sep; 113(1-3):15-32. PubMed ID: 15380644
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.
Joly Y; Koutrikas G; Ramos-Paque E; Zawati M; Gardy J; Hayden MR; Carleton BC
OMICS; 2011 Sep; 15(9):597-605. PubMed ID: 21728814
[TBL] [Abstract][Full Text] [Related]
13. [Application of reverse vaccinology in Schistosoma vaccine development: advances and prospects].
Feng XG; Sui CY; Yuan CX; Shao DH; Chen JX; Lin JJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):237-47. PubMed ID: 18038788
[TBL] [Abstract][Full Text] [Related]
14. Genomics and vaccine development.
Gay CG; Zuerner R; Bannantine JP; Lillehoj HS; Zhu JJ; Green R; Pastoret PP
Rev Sci Tech; 2007 Apr; 26(1):49-67. PubMed ID: 17633293
[TBL] [Abstract][Full Text] [Related]
15. Information technologies for vaccine research.
Brusic V; August JT; Petrovsky N
Expert Rev Vaccines; 2005 Jun; 4(3):407-17. PubMed ID: 16026252
[TBL] [Abstract][Full Text] [Related]
16. Proteomics for development of vaccine.
Adamczyk-Poplawska M; Markowicz S; Jagusztyn-Krynicka EK
J Proteomics; 2011 Nov; 74(12):2596-616. PubMed ID: 21310271
[TBL] [Abstract][Full Text] [Related]
17. Infectomics: genomics and proteomics of microbial infections.
Huang SH; Triche T; Jong AY
Funct Integr Genomics; 2002 Apr; 1(6):331-44. PubMed ID: 11957108
[TBL] [Abstract][Full Text] [Related]
18. The impact of genomics on vaccine design.
Scarselli M; Giuliani MM; Adu-Bobie J; Pizza M; Rappuoli R
Trends Biotechnol; 2005 Feb; 23(2):84-91. PubMed ID: 15661345
[TBL] [Abstract][Full Text] [Related]
19. The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.
Pezeshki A; Ovsyannikova IG; McKinney BA; Poland GA; Kennedy RB
Expert Rev Vaccines; 2019 Mar; 18(3):253-267. PubMed ID: 30700167
[TBL] [Abstract][Full Text] [Related]
20. New approaches and omics tools for mining of vaccine candidates against vector-borne diseases.
Kuleš J; Horvatić A; Guillemin N; Galan A; Mrljak V; Bhide M
Mol Biosyst; 2016 Aug; 12(9):2680-94. PubMed ID: 27384976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
